ReviewNPJ schizophrenia2018
Diagnosis and treatment of schizotypal personality disorder: evidence from a systematic review.
Review in NPJ schizophrenia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04764708 (Compassion and Metacognition Based Therapy for Schizotypal Personality Disorder), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Compassion and Metacognition Based Therapy for Schizotypal Personality Disorder: A Pilot Non-inferiority Randomized Controlled Trial on Repeated Measures.
Who cites it
17 citing papers in PubMed, 62 citations in OpenAlex.
- Omega-3 Supplementation Reduces Schizotypal Personality in Children: A Randomized Controlled Trial.Schizophrenia bulletin · 2024Trial
- Trial
- Association Between Primary Dysmenorrhea and Mental Health Traits: A Study Based on Multi-Phenotype Correlation Network and Mendelian Randomization Analysis in Female College Students.Phenomics (Cham, Switzerland) · 2025Article
- Schizotypal Traits in Children with Autism Spectrum Disorder and the Impact on Social, Emotional and Behavioral Functioning.Brain sciences · 2025Article
- A Latent Class Analysis of Personality Traits in Adults Experiencing Homelessness.Social work research · 2025Article
- Social Activity in Schizotypy: Measuring Frequency and Enjoyment of Social Events.Behavioral sciences (Basel, Switzerland) · 2024Article
- Psychosis superspectrum II: neurobiology, treatment, and implications.Molecular psychiatry · 2024Review
- Metacognition as a Transdiagnostic Determinant of Recovery in Schizotypy and Schizophrenia Spectrum Disorders.Behavioral sciences (Basel, Switzerland) · 2024Review
- Treatment of schizotypal disorder: a protocol for a systematic review of the evidence and recommendations for clinical practice.BMJ open · 2023Article
- Cognitive Processes and Resting-State Functional Neuroimaging Findings in High Schizotypal Individuals and Schizotypal Personality Disorder Patients: A Systematic Review.Brain sciences · 2023Review
- Protocol for the development and testing of the schiZotypy Autism Questionnaire (ZAQ) in adults: a new screening tool to discriminate autism spectrum disorder from schizotypal disorder.BMC psychiatry · 2023Article
- Correlates of obsessive-compulsive and related disorders symptom severity during the COVID-19 pandemic.Journal of psychiatric research · 2021Article
- Schizotypal personality disorder disguised as dissociative identity disorder.BMJ case reports · 2021Article
- An Inventory of Problems-29 (IOP-29) study investigating feigned schizophrenia and random responding in a British community sample.Psychiatry, psychology, and law : an interdisciplinary journal of the Australian and New Zealand Association of Psychiatry, Psychology and Law · 2021Article
- Validity and utility of Hierarchical Taxonomy of Psychopathology (HiTOP): I. Psychosis superspectrum.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2020Article
- Article
- High-resolution whole-brain magnetic resonance spectroscopic imaging in youth at risk for psychosis.Imaging neuroscience (Cambridge, Mass.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The main objective of this review was to evaluate studies on the diagnosis, treatment, and course of schizotypal personality disorder and to provide a clinical guidance on the basis of that evaluation. A systematic search in the PubMed/MEDLINE databases was conducted. Two independent reviewers extracted and assessed the quality of the data. A total of 54 studies were eligible for inclusion: 18 were on diagnostic instruments; 22, on pharmacological treatment; 3, on psychotherapy; and 13, on the longitudinal course of the disease. We identified several suitable and reliable questionnaires for screening (PDQ-4+ and SPQ) and diagnosing (SIDP, SIDP-R, and SCID-II) schizotypal personality disorder. Second-generation antipsychotics (mainly risperidone) were the most often studied drug class and were described as beneficial. Studies on the longitudinal course described a moderate remission rate and possible conversion rates to other schizophrenia spectrum disorders. Because of the heterogeneity of the studies and the small sample sizes, it is not yet possible to make evidence-based recommendations for treatment. This is a systematic evaluation of diagnostic instruments and treatment studies in schizotypal personality disorder. We conclude that there is currently only limited evidence on which to base treatment decisions in this disorder. Larger interventional trials are needed to provide the data for evidence-based recommendations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.